New Clinical Trial for Multiple Myeloma
The University of Maryland Greenebaum Cancer Center has opened a new Phase I/IIa clinical trial for multiple myeloma. The trial is designed to investigate the safety, bioactivity and anti-tumor effect of infusion of patients' own T cells that have been genetically modified to express a high affinity T cell receptor (TCR) specific for a type of tumor antigen (protein) known as a cancer testis antigen (CT antigen).
In this three-minute video, Dr. Aaron Rapoport, lead clinical investigator at the University of Maryland, explains the goal of the research.
This page was last updated: September 5, 2014